151 studies (12 from unattributed sources) on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Hk Peptides | 139 | 99.77% | View COA → |
| Lilipeptide | 135 | 99.56% | View COA → |
| Shanghai Sigma Audley Ssa | 126 | 99.45% | View COA → |
| Qing Li Peptide | 118 | 99.62% | View COA → |
| Unknown vendor (review) | 117 | 99.79% | View COA → |
| Nexaph | 115 | 99.41% | View COA → |
| Bfflist Amo | 105 | 99.71% | View COA → |
| Peptaris | 105 | 99.29% | View COA → |
Recent certificates: #26981 (99.69%) · #26982 (99.91%) · #27579 (99.87%) · #30753 (99.94%) · #38586 (99.75%) · #42718 (99.9%)
Manufacturers with published third-party certificates of analysis for Retatrutide. Open a vendor to see every batch we've verified.
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This comprehensive meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in treating both MASLD and MASH, addressing a critical unmet medical need. The significant rates of MASH …
Antiobesity medications offer a dual therapeutic strategy for managing both obesity and the often-coexisting MASLD, a condition with limited approved treatments. This review highlights their potential to become a corn…
Retatrutide's unprecedented efficacy in achieving substantial weight loss and improving metabolic markers positions it as a potential paradigm shift in obesity pharmacotherapy. Its unique mechanism as a triple agonist…
This review underscores the transformative potential of incretin-based therapies in combating the complex challenges of obesity and its comorbidities. By providing a comprehensive overview of their efficacy and safety…
These findings are highly significant, demonstrating retatrutide's potential as a comprehensive treatment for type 2 diabetes that not only manages blood sugar but also profoundly improves body composition by reducing…
This study provides crucial insights into the direct cardiac actions of retatrutide, suggesting it may have a beneficial or at least neutral impact on heart muscle function. Understanding these direct effects is vital…
This study provides compelling evidence that Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, offers direct and indirect benefits for kidney health in individuals with Type 2 Diabetes …
This comprehensive NMA provides crucial evidence supporting the superior efficacy of multi-receptor agonists like retatrutide and tirzepatide over single GLP-1 RAs for significant weight loss in adults with overweight…
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating…
This research provides crucial insights into the mechanism of action of retatrutide beyond its known effects on glucose and weight regulation, highlighting its potential role in lipid metabolism. Understanding that re…
This comprehensive review solidifies retatrutide's potential as a highly effective treatment for obesity, offering superior weight loss compared to existing therapies by targeting GLP-1, GIP, and glucagon receptors. T…
This review underscores the rapid evolution of pharmacotherapy for obesity, moving beyond traditional approaches to highly effective hormonal analogues that mimic natural satiety signals. The findings suggest a future…
This review highlights the significant potential of triple agonists to offer a more potent and comprehensive therapeutic strategy for obesity and its associated metabolic complications. The synergistic activation of G…
These findings suggest that Peptide-X could represent a powerful new therapeutic strategy for obesity and its associated metabolic complications. The significant and sustained weight loss, coupled with improvements in…
This study provides compelling, high-level evidence that incretin-based therapies offer significant cardiovascular benefits beyond glycemic control and weight management, specifically by consistently lowering blood pr…
This study highlights the potential of retatrutide to not only manage blood glucose but also to directly address the underlying appetite dysregulation in type 2 diabetes and obesity. By improving appetite control and …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This review critically underscores the importance of a holistic and integrated approach to weight management when utilizing powerful pharmacological tools like GLP-1 RAs. Preserving muscle mass is not merely an aesthe…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This review underscores the critical importance of understanding glucagon's pleiotropic (multiple) actions beyond glucose regulation. By elucidating shared mechanistic pathways, it provides a robust scientific rationa…
This review underscores the transformative potential of novel GLP-1-based medications to significantly advance the treatment of Type 2 Diabetes and Obesity. The enhanced efficacy in weight loss and glycemic control, c…
This publication is crucial because it details the blueprint for a comprehensive clinical program that could significantly expand the therapeutic options for several widespread and debilitating conditions. The multi-i…
This comprehensive review highlights the significant therapeutic potential of GLP-1 agonists as a multi-faceted treatment for PCOS, addressing not only metabolic dysfunction like insulin resistance and obesity but als…
This trial represents a pivotal step in exploring Retatrutide's potential beyond its established metabolic benefits, specifically targeting the complex pathology of CKD progression. If the TRANSCEND-CKD trial demonstr…
These findings underscore the critical importance of patient-reported outcomes in evaluating novel therapies, revealing that retatrutide offers substantial benefits beyond just weight loss. The observed improvements i…
This review underscores the transformative potential of engineered multi-agonists in the treatment landscape for obesity and metabolic disorders. By providing a conceptual blueprint for these advanced therapeutics, it…
This comprehensive systematic review provides a critical evidence base for clinicians and patients regarding the expected gastrointestinal side effects of anti-obesity medications. Understanding these common adverse e…
This review provides a critical roadmap for clinicians and researchers, consolidating the evidence for GLP-1 RAs as a cornerstone of modern obesity treatment. Understanding both their profound benefits and inherent li…
The findings from this review underscore a transformative era in the management of diabetic kidney disease, where novel therapies are significantly improving patient prognosis and quality of life. These advancements a…
This review provides a crucial, up-to-date resource for healthcare providers, offering a clear understanding of the current landscape of obesity pharmacotherapy. It underscores the paradigm shift towards highly effect…
Repurposing glucagon represents a significant paradigm shift in the treatment of obesity and type 2 diabetes, offering a novel and powerful approach beyond current single-target therapies. By harnessing its beneficial…
This comprehensive meta-analysis provides compelling evidence that Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, offers multi-faceted benefits for patients with the complex comorbidity of…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
The development of the WES represents a significant advancement in the assessment of the emotional dimensions of weight. This validated and reliable tool provides clinicians and researchers with a much-needed instrume…
This systematic review provides compelling evidence that next-generation incretin agonists offer superior efficacy for both weight management and glycemic control in overweight and obese individuals. The substantial w…
The findings from this study are profoundly significant, as they identify retatrutide as a potentially superior therapeutic agent for MC4R-deficient obesity, a condition notoriously difficult to manage. This MC4R defi…
Retatrutide's ability to simultaneously address obesity, insulin resistance, and multiple facets of MASH pathology is highly promising. This multi-target approach could offer a superior therapeutic strategy for a comp…
This comprehensive overview highlights Retatrutide's potential as a transformative therapeutic agent for managing the complex interplay of type 2 diabetes and obesity, offering a more holistic approach to metabolic he…
This network meta-analysis provides crucial comparative data on the efficacy and safety of various Glucagon Receptor Agonists, offering a more nuanced understanding than individual trials alone. The findings can help …
The development of Retatrutide represents a significant advancement in the pharmacological treatment of obesity and type 2 diabetes, offering a highly potent and comprehensive therapeutic option. Its unique triple-ago…
The findings from this Phase 1 study are critically important for the future development of LY3437943. Understanding the impact of hepatic impairment on drug pharmacokinetics is essential for establishing safe and eff…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…
Free, no account — handy when you're working with Retatrutide.